121 related articles for article (PubMed ID: 32198837)
21. One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent.
Kalkman DN; Woudstra P; den Heijer P; Menown IB; Erglis A; Suryapranata H; Arkenbout KE; Iñiguez A; van 't Hof AW; Muller P; Tijssen JG; de Winter RJ
Int J Cardiol; 2017 Jan; 226():60-64. PubMed ID: 27788391
[TBL] [Abstract][Full Text] [Related]
22. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Baldetti L; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Reimers B; Fabbiocchi F; Bartorelli A; Colombo A; Godino C
Catheter Cardiovasc Interv; 2020 Aug; 96(2):255-265. PubMed ID: 31905259
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis.
Kalkman DN; Kok MM; van der Heijden LC; Woudstra P; Beijk MAM; Tijssen JGP; von Birgelen C; de Winter RJ
EuroIntervention; 2017 Nov; 13(10):1202-1209. PubMed ID: 28870878
[TBL] [Abstract][Full Text] [Related]
24. Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR).
Kim Y; Oh SS; Jeong MH; Ahn Y; Kim JH; Hong YJ; Sim DS; Kim MC; Kim HS; Yun KH; Oh SK; Kim CJ; Cho MC
Cardiol J; 2019; 26(5):469-476. PubMed ID: 29745969
[TBL] [Abstract][Full Text] [Related]
25. Clinical Outcomes One Year and Beyond After Combination Sirolimus-Eluting Endothelial Progenitor Cell Capture Stenting During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction.
Sim HW; Thong EH; Tan HC; Low AF; Lee CH; Chan MY; Tay EL; Loh PH; Chan KH; Loh JP
Cardiovasc Revasc Med; 2019 Sep; 20(9):739-743. PubMed ID: 30442536
[TBL] [Abstract][Full Text] [Related]
26. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
27. The REMEDEE trial: 5-Year results on a novel combined sirolimus-eluting and endothelial progenitor cells capturing stent.
Haude M; Lee SWL; Worthley SG; Silber S; Verheye S; Rosli MA; Botelho R; Sim KH; Abizaid A; Mehran R;
Catheter Cardiovasc Interv; 2020 May; 95(6):1076-1084. PubMed ID: 31489742
[TBL] [Abstract][Full Text] [Related]
28. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative.
Chandrasekhar J; Baber U; Sartori S; Stefanini GG; Sarin M; Vogel B; Farhan S; Camenzind E; Leon MB; Stone GW; Serruys PW; Wijns W; Steg PG; Weisz G; Chieffo A; Kastrati A; Windecker S; Morice MC; Smits PC; von Birgelen C; Mikhail GW; Itchhaporia D; Mehta L; Kim HS; Valgimigli M; Jeger RV; Kimura T; Galatius S; Kandzari D; Dangas G; Mehran R
JACC Cardiovasc Interv; 2018 Jan; 11(1):53-65. PubMed ID: 29301648
[TBL] [Abstract][Full Text] [Related]
29. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Final five-year results of the patient-level pooled analysis from the TARGET I and TARGET II trials.
Li C; Guan C; Zhang R; Yang Y; Ma C; Li H; Chen S; Han Y; Xu B; Gao R;
Catheter Cardiovasc Interv; 2019 Feb; 93(S1):818-824. PubMed ID: 30565397
[TBL] [Abstract][Full Text] [Related]
31. Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies.
Guedeney P; Claessen BE; Mehran R; Kandzari DE; Aquino M; Davis S; Tamis L; Wang JC; Othman I; Gigliotti OS; Haghighat A; Singh S; Lopez M; Giugliano G; Horwitz PA; Sorrentino S; Underwood P; Allocco D; Meredith IT; Batchelor W
Catheter Cardiovasc Interv; 2019 Jul; 94(1):82-90. PubMed ID: 30666784
[TBL] [Abstract][Full Text] [Related]
32. One-year clinical results of the NANO registry: A multicenter, prospective all-comers registry study in patients receiving implantation of a polymer-free sirolimus-eluting stent.
Liu Y; Zhang Y; Li Y; Qi T; Pan D; Wang H; Liu C; Ma D; Fang Z; Zhang R; Mou F; Tao L;
Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():658-664. PubMed ID: 31961057
[TBL] [Abstract][Full Text] [Related]
33. Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials.
Lou Y; Yu Y; Xi Z; Gao Y; Liu W; Nie X
Cardiovasc Drugs Ther; 2019 Oct; 33(5):557-566. PubMed ID: 31773343
[TBL] [Abstract][Full Text] [Related]
34. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
[TBL] [Abstract][Full Text] [Related]
35. Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial.
Jakobsen L; Christiansen EH; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Madsen M; Raungaard B; Jensen SE; Christensen MK; Hansen HS; Jensen LO
Am Heart J; 2018 Aug; 202():49-53. PubMed ID: 29807307
[TBL] [Abstract][Full Text] [Related]
36. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
37. Three-year follow up of biodegradable polymer cobalt-chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: Pooled analysis of CREDIT II and CREDIT III trials.
Wang G; Ma G; Tao L; Yuan Z; Liu H; Hu X; Tong Q; Yu Z; Zhou X; Han Y
Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():565-571. PubMed ID: 31944543
[TBL] [Abstract][Full Text] [Related]
38. The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary Syndromes: Insights From Optical Coherence Tomography Imaging Analysis.
Jaguszewski M; Aloysius R; Wang W; Bezerra HG; Hill J; De Winter RJ; Karjalainen PP; Verheye S; Wijns W; Lüscher TF; Joner M; Costa M; Landmesser U
JACC Cardiovasc Interv; 2017 Mar; 10(5):489-499. PubMed ID: 28279316
[TBL] [Abstract][Full Text] [Related]
39. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial.
Iñiguez A; Chevalier B; Richardt G; Neylon A; Jiménez VA; Kornowski R; Carrie D; Moreno R; Barbato E; Serra-Peñaranda A; Guiducci V; Valdés-Chávarri M; Yajima J; Wijns W; Saito S;
Catheter Cardiovasc Interv; 2020 Feb; 95(2):175-184. PubMed ID: 31033154
[TBL] [Abstract][Full Text] [Related]
40. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
